Computational identification of antigen-binding antibody fragments

Journal of Immunology

Volumn 190, Issue 5, 2013, Pages 2327-2334

  Burkovitz, Anat ^a   Leiderman, Olga ^a   Sela Culang, Inbal ^a   Byk, Gerardo ^a   Ofran, Yanay ^a  

^a BAR ILAN UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; MATUZUMAB; MONOCLONAL ANTIBODY B12; TRASTUZUMAB;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CONTROLLED STUDY; PREDICTION; PRIORITY JOURNAL;

ANIMALS; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN-ANTIBODY COMPLEX; ANTIGENS; BINDING SITES, ANTIBODY; CHICKENS; CLONING, MOLECULAR; COMPLEMENTARITY DETERMINING REGIONS; DATABASES, PROTEIN; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; MODELS, MOLECULAR; PEPTIDES; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; THERMODYNAMICS;

EID: 84874247332     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200757     Document Type: Article

References (61)

1. Chan, A. C., and P. J. Carter. 2010. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10: 301-316.
2. Maynard, J., and G. Georgiou. 2000. Antibody engineering. Annu. Rev. Biomed. Eng. 2: 339-376.
3. Beck, A., T.Wurch, C. Bailly, and N. Corvaia. 2010. Strategies and challenges for the next generation of therapeutic antibodies. Nat. Rev. Immunol. 10: 345-352.
4. Nelson, A. L., and J. M. Reichert. 2009. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 27: 331-337.
5. Holliger, P., and P. J. Hudson. 2005. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 23: 1126-1136.
6. Hudson, P. J., and C. Souriau. 2003. Engineered antibodies. Nat. Med. 9: 129-134.
7. Porter, R. R. 1959. The hydrolysis of rabbit y-globulin and antibodies with crystalline papain. Biochem. J. 73: 119-126.
8. Bird, R. E., K. D. Hardman, J. W. Jacobson, S. Johnson, B. M. Kaufman, S. M. Lee, T. Lee, S. H. Pope, G. S. Riordan, and M. Whitlow. 1988. Singlechain antigen-binding proteins. Science 242: 423-426.
9. Jain, M., N. Kamal, and S. K. Batra. 2007. Engineering antibodies for clinical applications. Trends Biotechnol. 25: 307-316.
10. Utsumi, S., and F. Karush. 1964. The subunits of purified rabbit antibody. Biochemistry 3: 1329-1338.
11. Yoo, T. J., O. A. Roholt, and D. Pressman. 1967. Specific binding activity of isolated light chains of antibodies. Science 157: 707-709.
12. Ward, E. S., D. Güssow, A. D. Griffiths, P. T. Jones, and G. Winter. 1989. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341: 544-546.
13. Berry, M. J., and J. Davies. 1992. Use of antibody fragments in immunoaffinity chromatography. Comparison of FV fragments, VH fragments and paralog peptides. J. Chromatogr. A 597: 239-245.
14. Pereira, B., C. R. Benedict, A. Le, S. S. Shapiro, and P. Thiagarajan. 1998. Cardiolipin binding a light chain from lupus-prone mice. Biochemistry 37: 1430-1437.
15. Dubnovitsky, A. P., Z. I. Kravchuk, A. A. Chumanevich, A. Cozzi, P. Arosio, and S. P. Martsev. 2000. Expression, refolding, and ferritin-binding activity of the isolated VL-domain of monoclonal antibody F11. Biochemistry (Mosc.) 65: 1011-1018.
16. Rinfret, A., C. Horne, K. J. Dorrington, and M. Klein. 1985. Noncovalent association of heavy and light chains of human immunoglobulins. IV. The roles of the CH1 and CL domains in idiotypic expression. J. Immunol. 135: 2574-2581.
17. Polonelli, L., J. Pontón, N. Elguezabal, M. D. Moragues, C. Casoli, E. Pilotti, P. Ronzi, A. S. Dobroff, E. G. Rodrigues, M. A. Juliano, et al. 2008. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS ONE 3: e2371.
18. Kang, C. Y., T. K. Brunck, T. Kieber-Emmons, J. E. Blalock, and H. Kohler. 1988. Inhibition of self-binding antibodies (autobodies) by a VH-derived peptide. Science 240: 1034-1036.
19. Taub, R., J. C. Hsu, V. M. Garsky, B. L. Hill, B. F. Erlanger, and L. D. Kohn. 1992. Peptide sequences from the hypervariable regions of two monoclonal antiidiotypic antibodies against the thyrotropin (TSH) receptor are similar to TSH and inhibit TSH-increased cAMP production in FRTL-5 thyroid cells. J. Biol. Chem. 267: 5977-5984.
20. Saragovi, H. U., D. Fitzpatrick, A. Raktabutr, H. Nakanishi, M. Kahn, and M. I. Greene. 1991. Design and synthesis of a mimetic from an antibody complementarity-determining region. Science 253: 792-795.
21. Levi, M., M. Sällberg, U. Rudén, D. Herlyn, H. Maruyama, H.Wigzell, J. Marks, and B. Wahren. 1993. A complementarity-determining region synthetic peptide acts as a miniantibody and neutralizes human immunodeficiency virus type 1 in vitro. Proc. Natl. Acad. Sci. USA 90: 4374-4378.
22. Park, B. W., H. T. Zhang, C. Wu, A. Berezov, X. Zhang, R. Dua, Q. Wang, G. Kao, D. M. O'Rourke, M. I. Greene, and R. Murali. 2000. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18: 194-198.
23. Tsumoto, K., S. Misawa, Y. Ohba, T. Ueno, H. Hayashi, N. Kasai, H. Watanabe, R. Asano, and I. Kumagai. 2002. Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: tolerance of a CDR peptide to conformational changes of a target. FEBS Lett. 525: 77-82.
24. Feng, Y., D. Chung, L. Garrard, G. McEnroe, D. Lim, J. Scardina, K. McFadden, A. Guzzetta, A. Lam, J. Abraham, et al. 1998. Peptides derived from the complementarity-determining regions of anti-Mac-1 antibodies block intercellular adhesion molecule-1 interaction with Mac-1. J. Biol. Chem. 273: 5625-5630.
25. Feng, J., Y. Li, W. Zhang, and B. Shen. 2005. Rational design of potent mimic peptide derived from monoclonal antibody: antibody mimic design. Immunol. Lett. 98: 311-316.
26. Schellekens, G. A. 1996. Molecular aspects of antibody-antigen interactions: size reduction of a herpes simplex virus neutralizing antibody and its antigen. Doctoral dissertation, University of Groningen, Groningen, the Netherlands. Available at: http://www.rug.nl/science-and-society/library/search/ elekpubrug/ dissertaties/electronic?lang=en#ID-NL-S.
27. Lasonder, E., W. Bloemhoff, and G. W. Welling. 1994. Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance. J. Chromatogr. A 676: 91-98.
28. Bourgeois, C., J. B. Bour, L. S. Aho, and P. Pothier. 1998. Prophylactic administration of a complementarity-determining region derived from a neutralizing monoclonal antibody is effective against respiratory syncytial virus infection in BALB/c mice. J. Virol. 72: 807-810.
29. Williams, W. V., T. Kieber-Emmons, J. VonFeldt, M. I. Greene, and D. B. Weiner. 1991. Design of bioactive peptides based on antibody hypervariable region structures. Development of conformationally constrained and dimeric peptides with enhanced affinity. J. Biol. Chem. 266: 5182-5190.
30. Williams, W. V., D. A. Moss, T. Kieber-Emmons, J. A. Cohen, J. N. Myers, D. B. Weiner, and M. I. Greene. 1989. Development of biologically active peptides based on antibody structure. Proc. Natl. Acad. Sci. U S A 86: 5537-5541.
31. Qiu, X. Q., H. Wang, B. Cai, L. L. Wang, and S. T. Yue. 2007. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat. Biotechnol. 25: 921-929.
32. Tsumoto, K., Y. Nakaoki, Y. Ueda, K. Ogasahara, K. Yutani, K. Watanabe, and I. Kumagai. 1994. Effect of the order of antibody variable regions on the expression of the single-chain HyHEL10 Fv fragment in E. coli and the thermodynamic analysis of its antigen-binding properties. Biochem. Biophys. Res. Commun. 201: 546-551.
33. Kondo, H., M. Shiroishi, M. Matsushima, K. Tsumoto, and I. Kumagai. 1999. Crystal structure of anti-Hen egg white lysozyme antibody (HyHEL-10) Fvantigen complex. Local structural changes in the protein antigen and watermediated interactions of Fv-antigen and light chain-heavy chain interfaces. J. Biol. Chem. 274: 27623-27631.
34. Bogan, A. A., and K. S. Thorn. 1998. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280: 1-9.
35. Schmiedel, J., A. Blaukat, S. Li, T. Knöchel, and K. M. Ferguson. 2008. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 13: 365-373.
36. Cho, H. S., K. Mason, K. X. Ramyar, A. M. Stanley, S. B. Gabelli, D. W. Denney, Jr., and D. J. Leahy. 2003. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421: 756-760.
37. Zhou, T., L. Xu, B. Dey, A. J. Hessell, D. Van Ryk, S. H. Xiang, X. Yang, M. Y. Zhang, M. B. Zwick, J. Arthos, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
38. Shiroishi, M., K. Tsumoto, Y. Tanaka, A. Yokota, T. Nakanishi, H. Kondo, and I. Kumagai. 2007. Structural consequences of mutations in interfacial Tyr residues of a protein antigen-antibody complex. The case of HyHEL-10-HEL. J. Biol. Chem. 282: 6783-6791.
39. Ni, Y. G., S. Di Marco, J. H. Condra, L. B. Peterson, W. Wang, F. Wang, S. Pandit, H. A. Hammond, R. Rosa, R. T. Cummings, et al. 2011. A PCSK9- binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J. Lipid Res. 52: 78-86.
40. Berman, H. M., J. Westbrook, Z. Feng, G. Gilliland, T. N. Bhat, H. Weissig, I. N. Shindyalov, and P. E. Bourne. 2000. The Protein Data Bank. Nucleic Acids Res. 28: 235-242.
41. Kabat, E. A., T. T. Wu, H. Bilofsky, M. Reid-Miller, and H. M. Perry. 1983. Sequences of Proteins of Immunological Interest. National Institutes of Health, Bethesda, MD.
42. Ofran, Y. 2009. Prediction of protein interaction sites. In Computational Protein- Protein Interactions. R. Nussinov, and G. Schreiber, eds. CRC Press, Boca Raton, FL, p. 167-184.
43. Guerois, R., J. E. Nielsen, and L. Serrano. 2002. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol. 320: 369-387.
44. Krüger, D. M., and H. Gohlke. 2010. DrugScorePPI webserver: fast and accurate in silico alanine scanning for scoring protein-protein interactions. Nucleic Acids Res. 38(Web Server issue)W480-6.
45. Castro, B., J. R. Dormoy, G. Evin, and C. Selve. 1975. Reactifs de couplage peptidique I (1)-l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium (B.O.P.). Tetrahedron Lett. 16: 1219-1222.
46. Fields, G. B., and R. L. Noble. 1990. Solid phase peptide synthesis utilizing 9- fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Protein Res. 35: 161-214.
47. Albericio, F., R. P. Hammer, C. García-Echeverría, M. A. Molins, J. L. Chang, M. C. Munson, M. Pons, E. Giralt, and G. Barany. 1991. Cyclization of disulfidecontaining peptides in solid-phase synthesis. Int. J. Pept. Protein Res. 37: 402-413.
48. Stenberg, E., B. Persson, H. Roos, and C. Urbaniczky. 1991. Quantitative determination of surface concentration of protein with surface plasmon resonance using radiolabeled proteins. Journal of Colloid and Interface Science. 143: 513-526.
49. Myszka, D. G. 1997. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Curr. Opin. Biotechnol. 8: 50-57.
50. Fontenot, J. D., X. Tan, and D. M. Phillips. 1998. Structure-based design of peptides that recognize the CD4 binding domain of HIV-1 gp120. AIDS 12: 1413-1418.
51. Ponde, D. E., Z. Su, A. Berezov, H. Zhang, A. Alavi, M. I. Greene, and R. Murali. 2011. Development of anti-EGF receptor peptidomimetics (AERP) as tumor imaging agent. Bioorg. Med. Chem. Lett. 21: 2550-2553.
52. Cunningham, B. C., and J. A. Wells. 1989. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science 244: 1081-1085.
53. Laune, D., F. Molina, G. Ferrieres, J. C. Mani, P. Cohen, D. Simon, T. Bernardi, M. Piechaczyk, B. Pau, and C. Granier. 1997. Systematic exploration of the antigen binding activity of synthetic peptides isolated from the variable regions of immunoglobulins. J. Biol. Chem. 272: 30937-30944.
54. Kuroda, D., H. Shirai, M. Kobori, and H. Nakamura. 2008. Structural classification of CDR-H3 revisited: a lesson in antibody modeling. Proteins 73: 608-620.
55. Zhao, L., L. Wong, and J. Li. 2011. Antibody-specified B-cell epitope prediction in line with the principle of context-awareness. IEEE/ACM Trans. Comput. Biol. Bioinformatics 8: 1483-1494.
56. Johnson, G., and T. T. Wu. 1998. Preferred CDRH3 lengths for antibodies with defined specificities. Int. Immunol. 10: 1801-1805.
57. Perosa, F., E. Favoino, M. A. Caragnano, and F. Dammacco. 2004. Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. Immunol. Lett. 95: 145-153.
58. Almagro, J. C. 2004. Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J. Mol. Recognit. 17: 132-143.
59. Steinbergs, J., K. Kilchewska, U. Lazdina, A. Dishlers, V. Ose, M. Sällberg, and A. Tsimanis. 1996. Short synthetic CDR-peptides forming the antibody combining site of the monoclonal antibody against RNA bacteriophage fr neutralize the phage activity. Hum. Antibodies Hybridomas 7: 106-112.
60. Timmerman, P., R. Barderas, J. Desmet, D. Altschuh, S. Shochat, M. J. Hollestelle, J. W. Höppener, A. Monasterio, J. I. Casal, and R. H. Meloen. 2009. A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity. J. Biol. Chem. 284: 34126-34134.
61. Berezov, A., H. T. Zhang, M. I. Greene, and R. Murali. 2001. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structurefunction analysis. J. Med. Chem. 44: 2565-2574.